CAJ | 학술논문

目的：探讨益肾健脾汤对慢性萎缩性胃炎大鼠血清骨硬化蛋白水平和骨矿物质密度（bone mineral density, BMD）的影响。方法将Wistar大鼠按随机数字表法分为正常对照组、模型组、维酶素组、益肾健脾汤高、中和低剂量组。大鼠饮用0.1%氨水替代水180 d诱导慢性萎缩性胃炎。益肾健脾汤低、中、高剂量组分别灌胃益肾健脾汤7.5、15、30 g/(kg?d)，维酶素组灌胃维酶素混悬液0.28 g/(kg?d)，正常对照组和模型组灌胃等体积生理盐水，2 ml/d，1次/d，连续给药90 d。采用双能X线吸收法检测大鼠股骨BMD和骨矿物质含量（bone mineral content, BMC），应用酶联免疫吸附法检测血清骨硬化蛋白水平，放免法检测血清甲状旁腺素（parathyroid hormone, PTH）、降钙素（calcitonin, CT）。结果与正常对照组（10只）比较，模型组（9只）股骨 BMD[(0.168±0.007)g/cm2比(0.235±0.029)g/cm2]、BMC[(0.383±0.022）g 比(0.637±0.085)g]、血清CT浓度[(26.76±11.54)pg/ml比(33.85±13.12)pg/ml]均显著下降（P均＜0.05），血清骨硬化蛋白[(105.78±34.43)pg/ml比(71.51±23.21)pg/ml]和PTH[(11.52±4.34)ng/dl比(8.46±2.39)ng/dl]显著增高（P均＜0.05）。与模型组比较，益肾健脾汤低（10只）、中（10只）、高（9只）剂量组股骨BMD[(0.197±0.011)g/cm2、(0.201±0.017)g/cm2、(0.206±0.021)g/cm2比(0.168±0.007)g/cm2]、BMC[(0.538±0.036)g、(0.546±0.039)g、(0.569±0.048)g 比(0.383±0.022)g]、血清 CT 水平[(30.42±12.61)pg/ml、(31.35±12.75)pg/ml、(30.83±13.10)pg/ml比(26.76±11.54)pg/ml]显著增高（P均＜0.05）；血清骨硬化蛋白水平[(86.32±24.28)pg/ml、(87.65±24.75)pg/ml、(86.82±25.56)pg/ml 比(105.78±34.43)pg/ml]、血清PTH水平[(9.36±2.76)ng/dl、(9.76±2.85)ng/dl、(9.84±2.97)ng/dl比(11.52±4.34)ng/dl]显著降低（P 均＜0.05）。结论益肾健脾汤可降低慢性萎缩性胃炎大鼠血清骨硬化蛋白水平，对骨质疏松具有保护作用。目的：探討益腎健脾湯對慢性萎縮性胃炎大鼠血清骨硬化蛋白水平和骨礦物質密度（bone mineral density, BMD）的影響。方法將Wistar大鼠按隨機數字錶法分為正常對照組、模型組、維酶素組、益腎健脾湯高、中和低劑量組。大鼠飲用0.1%氨水替代水180 d誘導慢性萎縮性胃炎。益腎健脾湯低、中、高劑量組分彆灌胃益腎健脾湯7.5、15、30 g/(kg?d)，維酶素組灌胃維酶素混懸液0.28 g/(kg?d)，正常對照組和模型組灌胃等體積生理鹽水，2 ml/d，1次/d，連續給藥90 d。採用雙能X線吸收法檢測大鼠股骨BMD和骨礦物質含量（bone mineral content, BMC），應用酶聯免疫吸附法檢測血清骨硬化蛋白水平，放免法檢測血清甲狀徬腺素（parathyroid hormone, PTH）、降鈣素（calcitonin, CT）。結果與正常對照組（10隻）比較，模型組（9隻）股骨 BMD[(0.168±0.007)g/cm2比(0.235±0.029)g/cm2]、BMC[(0.383±0.022）g 比(0.637±0.085)g]、血清CT濃度[(26.76±11.54)pg/ml比(33.85±13.12)pg/ml]均顯著下降（P均＜0.05），血清骨硬化蛋白[(105.78±34.43)pg/ml比(71.51±23.21)pg/ml]和PTH[(11.52±4.34)ng/dl比(8.46±2.39)ng/dl]顯著增高（P均＜0.05）。與模型組比較，益腎健脾湯低（10隻）、中（10隻）、高（9隻）劑量組股骨BMD[(0.197±0.011)g/cm2、(0.201±0.017)g/cm2、(0.206±0.021)g/cm2比(0.168±0.007)g/cm2]、BMC[(0.538±0.036)g、(0.546±0.039)g、(0.569±0.048)g 比(0.383±0.022)g]、血清 CT 水平[(30.42±12.61)pg/ml、(31.35±12.75)pg/ml、(30.83±13.10)pg/ml比(26.76±11.54)pg/ml]顯著增高（P均＜0.05）；血清骨硬化蛋白水平[(86.32±24.28)pg/ml、(87.65±24.75)pg/ml、(86.82±25.56)pg/ml 比(105.78±34.43)pg/ml]、血清PTH水平[(9.36±2.76)ng/dl、(9.76±2.85)ng/dl、(9.84±2.97)ng/dl比(11.52±4.34)ng/dl]顯著降低（P 均＜0.05）。結論益腎健脾湯可降低慢性萎縮性胃炎大鼠血清骨硬化蛋白水平，對骨質疏鬆具有保護作用。
목적：탐토익신건비탕대만성위축성위염대서혈청골경화단백수평화골광물질밀도（bone mineral density, BMD）적영향。방법장Wistar대서안수궤수자표법분위정상대조조、모형조、유매소조、익신건비탕고、중화저제량조。대서음용0.1%안수체대수180 d유도만성위축성위염。익신건비탕저、중、고제량조분별관위익신건비탕7.5、15、30 g/(kg?d)，유매소조관위유매소혼현액0.28 g/(kg?d)，정상대조조화모형조관위등체적생리염수，2 ml/d，1차/d，련속급약90 d。채용쌍능X선흡수법검측대서고골BMD화골광물질함량（bone mineral content, BMC），응용매련면역흡부법검측혈청골경화단백수평，방면법검측혈청갑상방선소（parathyroid hormone, PTH）、강개소（calcitonin, CT）。결과여정상대조조（10지）비교，모형조（9지）고골 BMD[(0.168±0.007)g/cm2비(0.235±0.029)g/cm2]、BMC[(0.383±0.022）g 비(0.637±0.085)g]、혈청CT농도[(26.76±11.54)pg/ml비(33.85±13.12)pg/ml]균현저하강（P균＜0.05），혈청골경화단백[(105.78±34.43)pg/ml비(71.51±23.21)pg/ml]화PTH[(11.52±4.34)ng/dl비(8.46±2.39)ng/dl]현저증고（P균＜0.05）。여모형조비교，익신건비탕저（10지）、중（10지）、고（9지）제량조고골BMD[(0.197±0.011)g/cm2、(0.201±0.017)g/cm2、(0.206±0.021)g/cm2비(0.168±0.007)g/cm2]、BMC[(0.538±0.036)g、(0.546±0.039)g、(0.569±0.048)g 비(0.383±0.022)g]、혈청 CT 수평[(30.42±12.61)pg/ml、(31.35±12.75)pg/ml、(30.83±13.10)pg/ml비(26.76±11.54)pg/ml]현저증고（P균＜0.05）；혈청골경화단백수평[(86.32±24.28)pg/ml、(87.65±24.75)pg/ml、(86.82±25.56)pg/ml 비(105.78±34.43)pg/ml]、혈청PTH수평[(9.36±2.76)ng/dl、(9.76±2.85)ng/dl、(9.84±2.97)ng/dl비(11.52±4.34)ng/dl]현저강저（P 균＜0.05）。결론익신건비탕가강저만성위축성위염대서혈청골경화단백수평，대골질소송구유보호작용。
Objective To explore the effects of Yishen-Jianpi decoction on bone mineral density (BMD) and serum sclerostin level in chronic atrophic gastritis in rats. Methods Wistar rats were randomly divided into normal control group, model group, Weimeisu group, low-, medium-and high-dose Yishen-Jianpi Decoction groups. Chronic atrophic gastritis was induced via depriving of water by replacement with 0.1%ammonia water for 180 days. After modeling, the rats in the Yishen-Jianpi decoction groups of low-, medium-and high-dose received intragastric administration of Yishen-Jianpi decoction of 7.5, 15, 30 g/(kg?d), respectively;the Weimeisu group received intragastric administration of Weimeisu suspension 0.28 g/(kg?d);the normal control group and the model group received intragastric administration of equivalent volume of normal saline. After 90 d continuous administration the specimens were drawn. The femur BMD and BMC were detected with dual energy X-ray absorptiometry. The serum sclerostin level was measured with enzyme-linked immunosorbent assay. The serum levels of parathyroid hormone (PTH) and human calcitonin (CT) were detected with radioimmunoassay. Results Compared with the normal control group (n=10), the femur BMD (0.168 ± 0.007 g/cm2 vs. 0.235 ± 0.029 g/cm2), BMC (0.383 ± 0.022 g vs. 0.637 ± 0.085 g), and the serum CT level (26.76 ± 11.54 pg/m vs. 33.85 ± 13.12 pg/ml) in the model group (n=9) were significantly decreased (all P<0.05), while the serum level of sclerostin (105.78 ± 34.43 pg/ml vs. 71.51 ± 23.21 pg/ml) and PTH (11.52 ± 4.34 ng/dl vs. 8.46 ± 2.39 ng/dl) were significantly increased (all P<0.05). Compared with the model group, the femur BMD (0.197 ± 0.011 g/cm2, 0.201 ± 0.017 g/cm2, 0.206 ± 0.021 g/cm2 vs. 0.168 ± 0.007 g/cm2), BMC (0.538 ± 0.036 g, 0.546 ± 0.039 g, 0.569 ± 0.048 g vs. 0.383 ± 0.022 g), serum CT level (30.42 ± 12.61 pg/ml, 31.35 ± 12.75 pg/ml, 30.83 ± 13.10 pg/ml vs. 26.76 ± 11.54 pg/ml) in the Yishen-Jianpi decoction groups of low-(n=10), medium-(n=10) and high-dose (n=9) were significantly increased (all P<0.05), while serum levels of sclerostin (86.32 ± 24.28 pg/ml, 87.65 ± 24.75 pg/ml, 86.82 ± 25.56 pg/ml vs. 105.78 ± 34.43 pg/ml) and PTH (9.36 ± 2.76 ng/dl, 9.76 ± 2.85 ng/dl, 9.84 ± 2.97 ng/dl vs. 11.52 ± 4.34 ng/dl) were significantly decreased (all P<0.05). Conclusions Yishen-Jianpi decoction can reduce serum sclerostin level, and has protective effects against osteoporosis in chronic atrophic gastritis in rats.